Spire Healthcare
SPI.L (LSE)
Spire Healthcare stands out as a notable player in the UK private healthcare sector, appealing to investors looking for domestic exposure. With a 1-year return of 12.65% and a modest dividend yield of 0.67%, its financial health reflects a revenue increase of 4.9% to £796.7 million, though profits have faced some challenges. Recently downgraded by Credit Suisse, the company remains on the radar for those interested in the healthcare market.
Pros:
- Positive 1-year return
- Diverse healthcare services offered
Cons:
- Negative 5-year return
- Market cap relatively small
Spire Healthcare (SPI.L) may be suitable for investors seeking exposure to the UK private healthcare sector, particularly those looking for potential growth following a recent 1-year return of 12.65%. However, the company's mixed performance over the past five years and recent downgrade by Credit Suisse warrant careful consideration for those weighing the balance of risk and return in their investment strategy.